Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 7:82:ftad036.
doi: 10.1093/femspd/ftad036.

A review on Zika vaccine development

Zhe-Yu Peng  1 , Song Yang  2 , Hong-Zheng Lu  1 , Lin-Min Wang  1 , Ni Li  1 , Hai-Ting Zhang  1 , Si-Yu Xing  1 , Yi-Nan Du  1 , Sheng-Qun Deng  1
Affiliations
Review

A review on Zika vaccine development

Zhe-Yu Peng et al. Pathog Dis. .

Abstract

Zika virus (ZIKV), which belongs to the Flavivirus family, is mainly transmitted via the bite of Aedes mosquitoes. In newborns, ZIKV infection can cause severe symptoms such as microcephaly, while in adults, it can lead to Guillain‒Barré syndrome (GBS). Due to the lack of specific therapeutic methods against ZIKV, the development of a safe and effective vaccine is extremely important. Several potential ZIKV vaccines, such as live attenuated, inactivated, nucleic acid, viral vector, and recombinant subunit vaccines, have demonstrated promising outcomes in clinical trials involving human participants. Therefore, in this review, the recent developmental progress, advantages and disadvantages of these five vaccine types are examined, and practical recommendations for future development are provided.

Keywords: Mosquito-borne disease; Vaccine; Zika virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abbink P, Larocca RA, De La Barrera RA et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353:1129–32. 10.1126/science.aah6157. - DOI - PMC - PubMed
    1. Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. Nat Rev Micro. 2018;16:594–600. 10.1038/s41579-018-0039-7. - DOI - PMC - PubMed
    1. Amaral MP, Apostolico JDS, Tomita N et al. Homologous prime-boost with Zika virus envelope protein and poly (I:C) induces robust specific humoral and cellular immune responses. Vaccine. 2020;38:3653–64. 10.1016/j.vaccine.2020.03.037. - DOI - PubMed
    1. Annamalai AS, Pattnaik A, Sahoo BR et al. An attenuated Zika virus encoding non-glycosylated envelope (E) and non-structural protein 1 (NS1) confers complete protection against lethal challenge in a mouse model. Vaccines. 2019;7. 10.3390/vaccines7030112. - DOI - PMC - PubMed
    1. Annamalai AS, Pattnaik A, Sahoo BR et al. Zika virus encoding nonglycosylated envelope protein is attenuated and defective in neuroinvasion. J Virol. 2017;91. 10.1128/JVI.01348-17. - DOI - PMC - PubMed